TAGline Fall 2013
The Domestic Issue: We're at a stalemate. This issue of TAGline underscores TAG’s commitment to ending AIDS in the United States and realizing the goals of the National HIV/AIDS Strategy.
Roadmap for Childhood TB: Towards Zero Deaths
The World Health Organization, the International Union Against Tuberculosis and Lung Disease, the Stop TB Partnership and other partners will launch a roadmap outlining the path towards zero deaths from childhood tuberculosis.
First-Ever Targeted Roadmap Outlines Steps to End Childhood TB Deaths
Cost to end deaths from childhood TB estimated to be at least US$120 million annually WASHINGTON D.C. | October 1, 2013 -- The deaths of more than 74 000 children from tuberculosis (TB) could be prevented each year through measures outlined…
Treatment Action Group Criticizes European Refusal of New Drug to Fight Tuberculosis
Treatment Action Group (TAG) is disappointed by the failure of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) to recommend marketing approval for delamanid, a new drug in development for multidrug-resistant tuberculosis (MDR-TB).
2013 Pipeline Report
Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development: Written by Polly Clayden, Simon Collins, Colleen Daniels, Mike Frick, Mark Harrington, Tim Horn, Richard Jefferys, Karyn Kaplan, Erica Lessem, and Tracy Swan
TB Quick Facts
What Is Tuberculosis (TB)? Mycobacterium tuberculosis (MTB) is a type of bacterium (sometimes called a bug) that, for thousands of years, has caused TB disease (called consumption in the past). TB remains a major, if often unnoticed, problem today. TB…
Silent Crisis
On January 18, 2013, in Washington, D.C., TAG held a consultation on the domestic TB drug shortage crisis. The meeting was cosponsored by PATH, RESULTS, the Center for Global Health Policy, and the American Thoracic Society.
A Necessary Transformation
Simultaneous, not sequential, evaluations of novel drug regimens needed to speed TB treatment research By Lindsay McKenna An example of a multi-arm multi-stage (MAMS) phase II trial design. At the first interim analysis, novel regimen 2 is considered to lack…
Sanofi’s Double-Edged Sword
Rifapentine’s manufacturer helps to advance TB research while stalling access By Erica Lessem Sanofi-Aventis, manufacturer of the tuberculosis (TB) drug rifapentine (Priftin), can be credited for aiding research efforts to shorten and simplify treatment dosing for TB. However, the company’s…
TB Drugs for Children
Poor treatment options spur innovative research strategies By Polly Clayden, HIV i-Base Pediatric Drug Development Considerations: Pharmacokinetics There is an old adage in pediatric medicine: children are not little adults. This is particularly true when it comes to tuberculosis, for…